抗肿瘤药物处方在合并症成年癌症患者就诊期间：来自 2010-2016 年全国门诊医疗调查的结果。

Antineoplastic drugs prescription during visits by adult cancer patients with comorbidities: findings from the 2010-2016 National Ambulatory Medical Care Survey.

机构信息

Division of Health Care Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Rd. Rm. 3534, Hyattsville, MD, 20782, USA.

出版信息

Cancer Causes Control. 2020 Apr;31(4):353-363. doi: 10.1007/s10552-020-01281-5. Epub 2020 Feb 21.

DOI:10.1007/s10552-020-01281-5

PMID:32086673

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7448541/

Abstract

PURPOSE

Cancer treatment may be affected by comorbidities; however, studies are limited. The purpose of this study is to examine the frequency of comorbidities at visits by patients with breast, prostate, colorectal, and lung cancer and to estimate frequency of a prescription for antineoplastic drugs being included in the treatment received at visits by patients with cancer and concomitant comorbidities.

METHODS

We used nationally representative data on visits to office-based physicians from the 2010-2016 National Ambulatory Medical Care Survey and selected visits by adults with breast, prostate, colorectal, or lung cancer (n = 4,672). Nineteen comorbid conditions were examined. Descriptive statistics were calculated for visits by cancer patients with 0, 1, and ≥ 2 comorbidities.

RESULTS

From 2010-2016, a total of 10.2 million physician office visits were made annually by adult patients with breast, prostate, colorectal, or lung cancer. Among US visits by adult patients with breast, prostate, colorectal, or lung cancer, 56.3% were by patients with ≥ 1 comorbidity. Hypertension was the most frequently observed comorbidity (37.7%), followed by hyperlipidemia (19.0%) and diabetes (12.3%). Antineoplastic drugs were prescribed in 33.5% of the visits and prescribed at a lower percentage among visits by cancer patients with COPD (21.3% versus 34.3% of visits by cancer patients without COPD) and heart disease (22.7% versus 34.2% of visits by cancer patients without heart disease).

CONCLUSION

Our study provides information about comorbidities in cancer patients being treated by office-based physicians in an ambulatory setting.

摘要

目的

癌症治疗可能会受到合并症的影响，但相关研究有限。本研究旨在检查患有乳腺癌、前列腺癌、结直肠癌和肺癌的患者就诊时合并症的频率，并估计患有癌症和合并症的患者就诊时接受的治疗中包含抗肿瘤药物的处方频率。

方法

我们使用了 2010-2016 年全国门诊医疗调查中关于门诊医生就诊的全国代表性数据，并选择了患有乳腺癌、前列腺癌、结直肠癌或肺癌的成年人就诊（n=4672）。共检查了 19 种合并症。计算了患有 0、1 和≥2 种合并症的癌症患者就诊的描述性统计数据。

结果

2010-2016 年，每年有 1020 万成年乳腺癌、前列腺癌、结直肠癌或肺癌患者进行了门诊就诊。在美国，成年乳腺癌、前列腺癌、结直肠癌或肺癌患者的门诊就诊中，56.3%的患者患有≥1 种合并症。高血压是最常见的合并症（37.7%），其次是高血脂（19.0%）和糖尿病（12.3%）。抗肿瘤药物在 33.5%的就诊中被开具处方，而在患有 COPD（癌症患者中 COPD 就诊的 21.3%比无 COPD 就诊的 34.3%）和心脏病（癌症患者中心脏病就诊的 22.7%比无心脏病就诊的 34.2%）的癌症患者就诊中开具的比例较低。